MAPT and Alzheimer disease: Although it remains to be determined whether CSF AD biomarker levels and diagnostic cutoffs differ among various ethnic groups [40, 41], our study indicates that a fully automated immunoassay with minimal inter-laboratory variability can replace manual immunoassays to differentiate AD from CN populations, incorporate the framework’s amyloid/tau/neurodegeneration classification scheme for AD, and predict clinical progression.